Semaglutide and Hospital Stay Rates in People with Obesity and Heart Disease

Conflict of Interest Disclosures: Dr Nicholls reported consulting fees paid to his institution from Novo Nordisk during the conduct of the study; grants paid to his institution from Amgen, Anthera, AstraZeneca, Cerenis Therapeutics, Cyclarity Therapeutics, Eli Lilly, Esperion, Infraredx, LipoScience, NewAmsterdam Pharma, Novartis, Resverlogix, Roche, Sanofi-Regeneron, and The Medicines Company; and consulting fees paid to his institution from Abcentra, Akcea Therapeutics, Amarin, Anthera Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, CSL Behring, CSL Seqirus, Daiichi Sankyo, Eli Lilly, Esperion, Merck, Omthera Pharmaceuticals, Resverlogix, Sanofi-Regeneron, Scribe Therapeutics, Silence Therapeutics, Takeda, and Vaxxinity outside the submitted work. Dr Ryan reported personal fees from served on the Steering Committee for the SELECT trial from Novo Nordisk during the conduct of the study; holding stock options in Calibrate and Scientific Intake; and personal fees from AbbVie, Altimmune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Carmo Therapeutics/Roche/Regeneron, CinRx Pharma, Currax Pharmaceuticals, eMed, Epitomee Medical, Fractyl Health, Gila Therapeutics, Lilly, Nestle, Novo Nordisk, Source Bio, Structure Therapeutics, Tenvie, Wondr Health, and Zealand Pharma outside the submitted work. Dr Deanfield reported grants from Alzheimer’s Research UK and the British Heart Foundation; consulting honoraria from Aegerion Pharmaceuticals, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi; and serving as a member of the steering committees for the SOUL and SELECT trials outside the submitted work. Dr Lang reported grants from Novo Nordisk during the conduct of the study and grants from AstraZeneca, Boehringer Ingelheim, Moderna, and Roche Diagnostics outside the submitted work. Dr Lincoff reported Steering Committee fees from Novo Nordisk during the conduct of the study; consulting fees from Amgen and Eli Lilly; and research funding to institution from Esperion and Novartis outside the submitted work. Dr Lingvay reported funding for clinical trials to institution from Boehringer Ingelheim, Dexcom, Lilly, Novo Nordisk, Pfizer, and Roche; research-related consulting fees paid to institution from Novo Nordisk; and personal fees from AbbVie, Altimmune, Alveus Therapeutics, Amgen, Antag Therapeutics, AstraZeneca, Bain Capital, Bayer, Betagenon AB, Bioio Inc, Biomea, Boehringer Ingelheim, Boston Scientific, Carmot Therapeutics, Corxel, Cytoki Pharma, Eli Lilly, Genentech, Intercept, Janssen/Johnson & Johnson, Juvena Therapeutics, Keros Therapeutic Inc, Mediflix, Merck, Metsera, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, Shionogi, Skye Bioscience, Source Bio, Structure Therapeutics, Terns Pharma, The Comm Group, Verdiva Bio, WebMD, and Zealand Pharma outside the submitted work. Drs Lübker, Rasmussen, and Stensen reported being employees of and shareholders in Novo Nordisk A/S. Dr Weeke reported being an employee of Novo Nordisk . Dr Kahn reported personal fees from Novo Nordisk during the conduct of the study and personal fees from Amgen, Biomea Fusion, Eli Lilly, Merck, Neurimmune, and Oramed; and having stock options in AltPep outside the submitted work. No other disclosures were reported.